Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB07133 plus Sintilimab in Hepatocellular Carcinoma
NCT06141109Phase 2Recruiting
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co., Ltd.
- Start
- Jan 2022
- Primary completion
- Jul 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mbo7133 in hepatocellular carcinoma (HCC), sponsored by Xi'an Xintong Pharmaceutical Research Co., Ltd. Primary endpoints: Number of Participants with Dose Limiting Toxicity at 21 days, Treatment-Related Adverse Events and 1 more. Started Jan 2022; status: recruiting.
02
Drugs
mbo7133
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06141109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141109.